• Who it affects: Adults 40–60 years old are most frequently diagnosed, but GPA can occur at any age, including in children.
• Gender: Slight male predominance (≈55 % men).
• Prevalence: GPA affects about 3 cases per 100,000 people worldwide. Approximately 50–70 % of patients develop renal involvement at some point during their disease course.^[1][2]
• Geography: Higher incidence in Northern Europe and North America; rare in Asia and Africa, likely reflecting genetic and environmental differences.

Symptoms

Renal involvement may be the first sign of GPA or may develop after the classic sinus‑lung symptoms. The symptom list below includes both kidney‑specific and systemic features because they often occur together.

Kidney‑Specific Symptoms

• Hematuria (blood in urine): Often described as “cola‑colored” urine.
• Proteinuria (protein in urine): May be detected on routine dipstick testing.
• Reduced urine output (oliguria) or sudden anuria: Sign of rapidly progressive glomerulonephritis.
• Swelling (edema): Typically in the ankles, feet, or around the eyes due to fluid retention.
• Flank pain: Sometimes accompanies renal inflammation.

Systemic Symptoms (Often Present With Renal Disease)

• Upper respiratory: Chronic sinusitis, nasal crusting, epistaxis (nosebleeds), otitis media.
• Lower respiratory: Cough, hemoptysis (coughing up blood), shortness of breath.
• General: Fever, fatigue, weight loss, night sweats.
• Skin: Palpable purpura, livedo reticularis, or nodular lesions.
• Eyes: Conjunctivitis, scleritis, or nasal septum perforation leading to “saddle‑nose” deformity.
• Neurologic: Mononeuritis multiplex (patchy nerve damage), headaches.

Causes and Risk Factors

GPA is an autoimmune disease; the exact trigger is unknown, but research points to a combination of genetic susceptibility and environmental exposures.

Underlying Mechanisms

• ANCA antibodies: Most patients have anti‑proteinase 3 (PR3‑ANCA) antibodies that mistakenly target neutrophils, causing them to damage vessel walls.
• Genetic factors: Certain HLA‑DRB1 alleles (e.g., *HLA‑DRB1*04) increase risk.
• Environmental triggers: Silica dust, chronic nasal carriage of Staphylococcus aureus, and certain medications (e.g., propylthiouracil) have been linked to disease onset.

Who Is At Higher Risk?

• Adults aged 40‑60 years.
• People with a family history of autoimmune disease.
• Individuals with occupational exposure to silica, coal dust, or metal fumes.
• Chronic nasal carriage of S. aureus (studies show higher relapse rates).

Diagnosis

Early recognition is crucial because renal GPA can progress to irreversible kidney failure within weeks. Diagnosis combines clinical assessment, laboratory testing, imaging, and tissue biopsy.

Laboratory Tests

• ANCA testing: ELISA for PR3‑ANCA (c‑ANCA) – positive in 80–90 % of renal GPA cases.^[3]
• Urinalysis: Detects hematuria, proteinuria, and red‑cell casts.
• Serum creatinine & eGFR: Evaluates kidney function; rapid rise suggests crescentic glomerulonephritis.
• Complete blood count (CBC): May reveal anemia of chronic disease or leukocytosis.
• Inflammatory markers: Elevated ESR and CRP.

Imaging

• Chest X‑ray/CT: Looks for pulmonary nodules, cavitations, or infiltrates that often accompany GPA.
• Renal ultrasound: Usually normal early; may show enlarged kidneys with increased echogenicity in advanced disease.

Biopsy – The Gold Standard

A renal (or sometimes nasal) biopsy demonstrates pauci‑immune necrotizing crescentic glomerulonephritis. Absence of immune complex deposition (negative immunofluorescence) helps differentiate GPA from lupus nephritis or IgA nephropathy.

Classification Criteria

The 2022 ACR/EULAR GPA classification criteria require ≥5 points from a combination of ANCA status, clinical features, and biopsy findings.^[4]

Treatment Options

Therapy aims to induce remission quickly, then maintain it with lower‑dose medication while preserving kidney function.

Induction Therapy (First 3–6 months)

• High‑dose glucocorticoids: Intravenous methylprednisolone 500–1000 mg daily for 3 days, then oral prednisone 1 mg/kg/day tapered over weeks.
• Rituximab: 375 mg/m² weekly × 4 or 1 g IV on days 0 and 14. Equal or superior to cyclophosphamide for renal GPA and preferred in patients desiring fertility preservation.^[5]
• Cyclophosphamide: Oral 2 mg/kg/day or IV pulse (15 mg/kg every 2–3 weeks) for 3–6 months; used when rituximab contraindicated.
• Plasma exchange (PLEX): Considered for patients with severe renal impairment (creatinine >5 mg/dL) or pulmonary hemorrhage; data (PEXIVAS trial) suggest modest benefit in select high‑risk groups.^[6]

Maintenance Therapy (6 months – several years)

• Rituximab: 500 mg IV every 6 months or 1 g every 6 months, guided by ANCA titers and clinical status.
• Aza­thyoprine: 2 mg/kg/day – most common oral agent; monitor liver function and blood counts.
• Mycophenolate mofetil (MMF):** Alternative for patients intolerant of azathioprine.
• Low‑dose glucocorticoids: Usually ≤10 mg prednisone daily, tapered to the lowest effective dose.

Adjunctive Measures

• Trimethoprim‑sulfamethoxazole prophylaxis to prevent S. aureus infections and reduce relapse rates.
• Vaccinations (influenza, pneumococcal, COVID‑19) – administered before immunosuppression when possible.
• Bone health: Calcium + vitamin D and bisphosphonates if on chronic steroids.
• Blood pressure control (target <130/80 mmHg) using ACE inhibitors or ARBs, which also reduce proteinuria.

Living with Wegener’s Kidney Disease

Managing a chronic, potentially relapsing illness involves medical, emotional, and practical strategies.

Daily Management Tips

• Medication adherence: Use pill organizers, set alarms, and keep a medication list for every health‑care visit.
• Monitoring: Check blood pressure daily, record urine color and volume, and note any new swelling or fatigue.
• Laboratory follow‑up: Routine CBC, CMP, urinalysis, and ANCA titers every 1–3 months during remission.
• Dietary considerations:
  • Limit sodium to <1500 mg/day to control edema and blood pressure.
  • Maintain adequate protein (0.8–1.0 g/kg body weight) – not too low, as it may worsen malnutrition.
  • Stay hydrated unless your doctor advises fluid restriction for advanced kidney disease.
• Exercise: Low‑impact activities (walking, swimming, stationary cycling) 150 min/week enhance cardiovascular health and reduce steroid‑related bone loss.
• Stress reduction: Mindfulness, yoga, or counseling can help cope with the anxiety of chronic disease.
• Support networks: Join GPA patient groups (e.g., Vasculitis Foundation) for peer support.

Fertility & Family Planning

Rituximab and cyclophosphamide can affect fertility. Discuss sperm banking or egg preservation before starting cytotoxic therapy. Women should avoid pregnancy during active disease and for at least 6 months after cyclophosphamide.

Travel and Lifestyle

• Carry a medical alert card describing “Granulomatosis with polyangiitis – kidney involvement – on immunosuppression.”
• Plan for medication storage (avoid extreme heat).
• Consult your rheumatologist before international travel; ensure you have adequate supply of meds and prophylactic antibiotics if needed.

Prevention

Because GPA is an autoimmune disease, true primary prevention is not possible. However, minimizing known triggers and early detection can reduce disease severity.

• Smoking cessation: Smoking is associated with higher relapse rates.
• Avoid occupational silica exposure: Use protective masks and adequate ventilation.
• Prompt treatment of chronic sinus infections: Regular ENT follow‑up can reduce bacterial colonisation that may stimulate ANCA production.
• Regular health screenings: Annual urinalysis for patients with known GPA, even during remission, helps catch early renal involvement.

Complications

If left untreated or poorly controlled, Wegener’s kidney disease can lead to serious, sometimes irreversible problems.

• End‑stage renal disease (ESRD): Occurs in ~25 % of renal GPA patients within 5 years without adequate therapy.
• Hypertension: Chronic kidney damage often leads to resistant high blood pressure.
• Infection: Immunosuppressive drugs increase risk of bacterial, viral (e.g., CMV), and opportunistic infections.
• Malignancy: Long‑term cyclophosphamide exposure raises risk of bladder cancer; regular urine cytology is recommended.
• Bone loss & fractures: Steroid‑induced osteoporosis.
• Cardiovascular disease: Chronic inflammation accelerates atherosclerosis.

When to Seek Emergency Care

References

1. Mayo Clinic. “Granulomatosis with polyangiitis (Wegener’s).” Updated 2023. Link.
2. CDC. “Vasculitis.” 2022. Link.
3. Frederick, T.D., et al. “ANCA testing for vasculitis: a review of current methods.” *Clin Chem Lab Med.* 2022;60(6):905‑915.
4. Hampton, A., et al. “2022 ACR/EULAR Classification Criteria for Granulomatosis with Polyangiitis.” *Arthritis Rheumatol.* 2022;74(3):349‑358.
5. Stone, J.H., et al. “Rituximab versus Cyclophosphamide for ANCA‑Associated Vasculitis.” *N Engl J Med.* 2010;363:221–232.
6. Walsh, M., et al. “Plasma exchange for severe ANCA‑associated vasculitis (PEXIVAS): a randomized trial.” *Lancet.* 2020;395:1173‑1184.